Clinical results and economic considerations of 68Ga-PSMA and radiolabeled choline in prostate cancer

Laura Evangelista, Maria Giuseppina Bonavina, Emilio Bombardieri

Research output: Contribution to journalComment/debatepeer-review


In recent years there was an impressive improvement in the options for the management of patients with prostate cancer. Nuclear Medicine has significantly enriched its diagnostic options, both in radiopharmacy and in instrumentation, in order to accurately target prostatic cancer cells, thus rendering the physicians able to adopt the best therapeutic strategy. In the present analysis, we have evaluated the available published data about 68Ga-PSMA and radio-labeled choline, two radiopharmaceutical agents for positron emission tomography/computed tomography (PET/CT) examination, by reporting clinical information and considering data about legal, economic and organization aspects.

Original languageEnglish
Pages (from-to)47-49
Number of pages3
JournalNuclear Medicine and Biology
Publication statusPublished - Jul 1 2017


  • 18F-choline
  • 68Ga-PSMA, 11C-choline
  • Costs
  • Pet/Ct
  • Prostate cancer

ASJC Scopus subject areas

  • Molecular Medicine
  • Radiology Nuclear Medicine and imaging
  • Cancer Research


Dive into the research topics of 'Clinical results and economic considerations of <sup>68</sup>Ga-PSMA and radiolabeled choline in prostate cancer'. Together they form a unique fingerprint.

Cite this